Abstract:The microtubule-associated Tau protein aggregates into insoluble paired helical filaments (PHFs) that deposit as neurofibrillary tangles (NFTs) which may cause neurodegeneration in brains of those with Alzheimer's disease(AD) and other related tauopathies; therefore, the drug discovery targeting on Tau protein has attracted an increasing number of researchers. In the last decade, most of the studies were focused on the approach to search for inhibitors of phosphorylation kniases, while only few put their eyes on the approach to discover inhibitors of Tau self-aggregation process. Phenylthiazolyl-Hydrazide (PTH) with the same core structure is a kind of molecules that directly inhibit Tau self-aggregation process. To illuminate the relationship between the structure of R-groups and molecular activities, and design new molecules with higher activity than the template molecule, topomer CoMFA was employed in three-dimensional quantitative structure-activity relationship (3D-QSAR) studies of 26 phenylthiazolyl-hydrazides(PTH) derivatives as Tau protein inhibitors. The Topomer CoMFA model has good fitting ability and predictive ability. The number of principal components, r(2), q(2) r(pred)(2), SEE and F of the Topomer CoMFA model were 5, 0. 976, 0. 603, 0. 795, 0. 110 and 115. 778, respectively. The model was used to search R-groups with special activity contribution from ZINC database. By No. 1 molecule filtering, there were 9 R-1-groups and 2 R-2-groups with contribution values rising by 20%. We employed the 9 R-1-groups and 2 R-2-groups to alternately substitutes for the R-1 and R-2 of sample 1; as a result, we got a total of 18 new compounds and further predicted their activities using the Topomer CoMFA model obtained, and the activity of 15 of them were higher than that of the template molecule. This research showed that Topomer search could be effectively used in molecular design; meanwhile, the molecules designed provide new candidate drugs for drug development of Alzheimer's disease.

Molecular Hairpin: a Possible Model for Inhibition of Tau Aggregation by Tannic Acid.

New Strategy for Reducing Tau Aggregation Cytologically by A Hairpinlike Molecular Inhibitor, Tannic Acid Encapsulated in Liposome

Tannic acid as a biphasic modulator of tau protein liquid-liquid phase separation

Molecular Deformation is a Key Factor in Screening Aggregation Inhibitor for Intrinsically Disordered Protein Tau

Atomic insights into the inhibition of R3 domain of tau protein by epigallocatechin gallate, quercetin and gallic acid

IDENTIFICATION OF A SMALL MOLECULE INHIBITOR OF TAU AGGREGATION

Dynamic-Inspired Perspective on the Molecular Inhibitor of Tau Aggregation by Glucose Gallates Based on Human Neurons

Thonningianin A from Penthorum chinense Pursh as a targeted inhibitor of Alzheimer's disease‐related β‐amyloid and Tau proteins

Artificial intelligence assisted identification of potential tau aggregation inhibitors: ligand- and structure-based virtual screening, in silico ADME, and molecular dynamics study

ChemInform Abstract: Tau Protein Associated Inhibitors in Alzheimer Disease

Exploring Tau Fibril-Disaggregating and Antioxidating Molecules Binding to Membrane-Bound Amyloid Oligomers Using Machine Learning-Enhanced Docking and Molecular Dynamics

Evaluation of Heptelidic Acid As a Potential Inhibitor for Tau Aggregation-Induced Alzheimer's Disease and Associated Neurotoxicity

Inhibitor discovery targeting the intermediate structure of beta-amyloid peptide on the conformational transition pathway: implications in the aggregation mechanism of beta-amyloid peptide.

Tau Protein Associated Inhibitors in Alzheimer Disease

The Structure Biology of Tau and Clue for Aggregation Inhibitor Design

Inhibitory Effect of TA9902 on Amyloid Β- Peptide 1 -42 Aggregation by Fourier- Transform Infrared Spectroscopy Study

Tryptanthrin Analogs Substoichiometrically Inhibit Seeded and Unseeded Tau4RD Aggregation

Di-caffeoylquinic acid: a potential inhibitor for amyloid-beta aggregation

Tau-Targeted Multifunctional Nanoinhibitor for Alzheimer's Disease.

Stabilization of Monomeric Tau Protein by All D-Enantiomeric Peptide Ligands as Therapeutic Strategy for Alzheimer's Disease and Other Tauopathies

Molecular Design of PTH Derivatives as Tau Protein Inhibitors Using R-Group Search Technology